- Home
- CGO vs FBIO Comparison
CGO vs FBIO Comparison
Compare CGO & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CGO | FBIO |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.9M | 113.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CGO | FBIO |
|---|---|---|
| Price | $12.03 | $3.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 34.7K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 9.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $62,303,000.00 |
| Revenue This Year | N/A | $29.71 |
| Revenue Next Year | N/A | $49.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.90 | $1.33 |
| 52 Week High | $10.93 | $4.53 |
Technical Indicators
Market Signals| Indicator | CGO | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 67.01 | 52.72 |
| Support Level | $11.38 | $3.25 |
| Resistance Level | $12.10 | $4.53 |
| Average True Range (ATR) | 0.12 | 0.32 |
| MACD | 0.05 | -0.09 |
| Stochastic Oscillator | 88.60 | 38.88 |
Price Performance
Historical ComparisonAbout CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.